Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 10, Pages 1289-1300Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.10.1289
Keywords
antiprotease therapy; endoproteolysis; proprotein convertases; proteases; protease inhibitors; proteolytic processing; therapeutic targets
Categories
Funding
- Canadian Institute for Health Research, the Natural Sciences and Engineering Council of Canada
- Heart and Stroke Ontario, Canada Stroke Network and the Strauss Foundation.
Ask authors/readers for more resources
Background: Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases. Altered expression of these enzymes in experimental animal models and in humans has been associated with numerous pathologies, including infertility, developmental defects, metabolic dysfunctions, cancer, cardiovascular diseases and infectious diseases. Objective: To review experimental evidence of the therapeutic potential of proprotein convertase inhibitors or silencers. Conclusions: Several potent inhibitors have been developed and successfully tested. Their therapeutic use must await further improvements in potency, selectivity, cellular delivery and tissue targeting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available